fosdenopterin MoCD Nulibry
Selected indexed studies
- Molybdenum Cofactor Deficiency. (, 1993) [PMID:34870926]
- Fosdenopterin: First Approval. (Drugs, 2021) [PMID:33909276]
- Molybdenum cofactor deficiency. (Mol Genet Metab, 2016) [PMID:26653176]
_Worker-drafted node — pending editorial review._
Connections
fosdenopterin MoCD Nulibry is a side effect of
Sources
- Molybdenum Cofactor Deficiency. (1993) pubmed
- Fosdenopterin: First Approval. (2021) pubmed
- Molybdenum cofactor deficiency. (2016) pubmed
- Increased Survival in Patients With Molybdenum Cofactor Deficiency Type A Treated With Cyclic Pyranopterin Monophosphate. (2025) pubmed
- Consensus guidelines for the diagnosis and management of isolated sulfite oxidase deficiency and molybdenum cofactor deficiencies. (2024) pubmed
- Molybdenum Cofactor Deficiency in Humans. (2022) pubmed
- Early Neonatal Fosdenopterin Treatment for Molybdenum Cofactor Deficiency Type A: New Insights into Its Natural History and Potential Role for Fetal Therapy. (2025) pubmed
- S-sulfocysteine/NMDA receptor-dependent signaling underlies neurodegeneration in molybdenum cofactor deficiency. (2017) pubmed
- Early postnatal hepatocyte transplantation in a child with molybdenum cofactor deficiency type B. (2025) pubmed
- Treatable Neonatal Molybdenum Cofactor Deficiency: Rapid Demise Despite Rapid Biochemical Diagnosis. (2026) pubmed